Cizzle Biotechnology Holdings PLCFRA Cizzle Biotechnology Stock Report

Cizzle Biotechnology Holdings Plc is a holding company, which is actively seeking for new investment opportunity. The Company’s proof-of-concept prototype test is based on the ability to detect a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. The company helps to reduce the need for repeated computed tomography (CT) scanning. The firm provides its product AZD1656 is treatment for COVID19 patients. AZD1656 is an immunomodulator which damps down the inflammatory response characteristic of coronavirus disease (COVID-19) infection, while enhancing the part of the immune response. The firm has developed a prototype confirmative test to address the false positive rates of CT scanning to avoid unnecessary invasive testing.